 | This article may rely excessively on sources too closely associated with the subject , potentially preventing the article from being verifiable and neutral.(October 2020) |
Pier Paolo Pandolfi | |
|---|---|
 | |
| Born | Italy |
| Alma mater | University of Perugia, Italy |
| Scientific career | |
| Fields | |
| Institutions | |
| Website | pandolfilab |
Pier Paolo Pandolfi is an Italian doctor, geneticist, molecular biologist, and cancer researcher.
Originally from Rome, Italy, Pandolfi studied medicine at the University of Perugia in Umbria in central Italy, where he began his research into acute promyelocytic leukemia. [1] [2] He received his MD in 1989, his Ph.D. in 1995, and did postgraduate work at the Royal Postgraduate Medical School. [2]
In 1994, Pandolfi moved his research to the Memorial Sloan-Kettering Cancer Center in New York City and joined the faculty of Weill Cornell Graduate School of Medical Sciences as a professor of molecular biology, pathology, and human genetics. [1] Pandolfi eventually became the chair of cancer biology and genetics and the head of the molecular and developmental biology lab at Sloan-Kettering. [1]
Pandolfi left Sloan-Kettering in 2007 to become the director of Beth Israel Deaconess Medical Center's new cancer genetics program. [1] [3] While there he was the George C. Reisman professor of medicine at Harvard Medical School and an associate member of the Broad Institute of MIT and Harvard University. [4] [5] He became the director of the BIDMC Cancer Center and Cancer Research Institute in 2013. [4] [6] Pandolfi received the Pezcoller Foundation-American Association for Cancer Research International Award for Cancer Research in 2011 and was elected as an Fellow of the American Association for the Advancement of Science in 2017 in recognition of his cancer research. [4] [7]
Between fall 2018 and spring 2019, Pandofi pursued an inappropriate relationship with a postdoctoral researcher. [8] A Harvard internal investigation referred him to an external evaluation service that allowed him to return to work. [8] In December 2019, Pandolfi resigned from Harvard. [8] In May 2020, he became the director of the Institute of Cancer at Renown Health, joined the faculty of the Desert Research Institute, and was announced as the scientific director of the Veneto Institute of Molecular Medicine (VIMM) in Padua, Italy. [8] [2] The VIMM scientific advisory board resigned in protest because they had not been consulted before Pandolfi's appointment. [8] The VIMM foundation reversed their decision to appoint Pandolfi in June 2020, and he resigned from his position at the Desert Research institute. [8]
Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School and one of the founding members of Beth Israel Lahey Health. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital. Among independent teaching hospitals, Beth Israel Deaconess Medical Center has ranked in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.
The Eli and Edythe L. Broad Institute of MIT and Harvard, often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and it partners with the Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
Mark Ptashne is a molecular biologist. He is the Ludwig Chair of Molecular Biology at Memorial Sloan–Kettering Cancer Center in New York City.
Paolo Boffetta is an Italian epidemiologist. He is doing research on cancer and other chronic diseases, where he contributed to the understanding of the role of occupation, environment, alcohol, smoking and nutrition in disease development. In 2013, his candidacy for the position of Director of France's national center for research in epidemiology and public health was withdrawn as a result of his extensive consulting work for industry in lawsuits involving asbestos.
Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.
Thomas J. Kelly is an American cancer researcher whose work focuses on the molecular mechanisms of DNA replication. Kelly is director of the Sloan-Kettering Institute, the basic research arm of the Memorial Sloan-Kettering Cancer Center. He holds the Center's Benno C. Schmidt Chair of Cancer Research.
Simon N. Powell is a British cancer researcher and radiation oncologist residing in New York City.
Michael B. Yaffe is an American scientist, professor, surgeon, and retired U.S. Army Reserve Medical Corps Colonel. He is currently the David H. Koch Professor of Biology & Biological Engineering at MIT and a trauma surgeon at the Beth Israel Deaconess Medical Center. In 2016, the United States Army awarded him the Bronze Star Medal for his services as a trauma surgeon on active duty in Afghanistan. He also treated many of the victims of the Boston Marathon bombing.
The Szent-Györgyi Prize for Progress in Cancer Research, established by National Foundation for Cancer Research (NFCR) and named in honor of Albert Szent-Györgyi, Nobel laureate and co-founder of NFCR, has been awarded annually since 2006 to outstanding researchers whose scientific achievements have expanded the understanding of cancer and whose vision has moved cancer research in new directions. The Szent-Györgyi Prize honors researchers whose discoveries have made possible new approaches to preventing, diagnosing and/or treating cancer. The Prize recipient is honored at a formal dinner and award ceremony and receives a $25,000 cash prize. In addition, the recipient leads the next "Szent-Györgyi Prize Committee" as honorary chairman.
Kenneth Offit is an American cancer geneticist and oncologist known for his discoveries with respect to the genetic bases of breast, colorectal, and lymphoid cancers. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute and Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College. He was previously a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.
Carlos Cordon-Cardo is a Spanish-born American physician and scientist known for his research in experimental pathology and molecular oncology. He holds the "Irene Heinz Given and John LaPorte Given" Chair in Pathology at Mount Sinai School of Medicine.
Paul Talalay was a John Jacob Abel Distinguished Service Professor of Pharmacology and director of the Laboratory for Molecular Sciences at the Johns Hopkins School of Medicine in Baltimore. He was the founder of the Brassica Chemoprotection Laboratory for the study of edible plants that induce protective enzyme activity in the body and may help prevent the development of cancer.
Marcel R.M. van den Brink is a Dutch oncologist and researcher known for his research in hematopoietic stem cell transplantation for cancer patients.
Nathanael S. Gray is an American chemist. He serves as Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana–Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego. C4 Therapeutics, which offered IPO in 2020, was founded based on the research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gray, while he was professor at Harvard Medical School. Before moving to Stanford University, Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm. In 2020, Gray Lab permanently moved to Stanford University, that was stated by Stuart Schreiber, co-founder of Broad Institute as "Stanford's huge gain".
Scott William Lowe is Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is recognized for his research on the tumor suppressor gene, p53, which is mutated in nearly half of cancers.
Gregory James Hannon is a professor of molecular cancer biology and director of the Cancer Research UK Cambridge Institute at the University of Cambridge. He is a Fellow of Trinity College, Cambridge while also serving as a director of cancer genomics at the New York Genome Center and an adjunct professor at Cold Spring Harbor Laboratory.
Kathryn Virginia Anderson was an American developmental biologist researching about the various gene and protein interactions that guide the process of embryogenesis and especially neurulation.
Scott Neal Keeney is an American molecular biologist.
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
